DE4328374A1 - Use of an extract from the leaves of Ginkgo biloba - Google Patents
Use of an extract from the leaves of Ginkgo bilobaInfo
- Publication number
- DE4328374A1 DE4328374A1 DE19934328374 DE4328374A DE4328374A1 DE 4328374 A1 DE4328374 A1 DE 4328374A1 DE 19934328374 DE19934328374 DE 19934328374 DE 4328374 A DE4328374 A DE 4328374A DE 4328374 A1 DE4328374 A1 DE 4328374A1
- Authority
- DE
- Germany
- Prior art keywords
- leaves
- ginkgo biloba
- extract
- ginkgo
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 12
- 235000008100 Ginkgo biloba Nutrition 0.000 title claims abstract description 11
- 244000194101 Ginkgo biloba Species 0.000 title claims abstract description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 241000218628 Ginkgo Species 0.000 claims description 3
- 235000011201 Ginkgo Nutrition 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000010257 gingium Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Gegenstand der Erfindung ist eine neue Verwendung des Extrak tes aus den Blättern von Ginkgo biloba.The invention relates to a new use of the extract tes from the leaves of Ginkgo biloba.
Die Multiple Sklerose ist eine bis heute noch wenig erforsch te Krankheit. Wirksame Therapievorschläge konnten bislang auf grund fehlender Ursachenkenntnis nicht gemacht werden. Nach bisherigen Erkenntnissen handelt es sich bei der Multip len Sklerose um eine Erkrankung des zentralen Nerversystems, bei der die eigenen weißen Blutkörperchen die Myellin-Hüllen der Nervenfasern zerstören.Multiple sclerosis has so far been little researched te disease. Effective therapy proposals have so far been able to due to a lack of causal knowledge. According to current knowledge, the Multip is len sclerosis around a disease of the central nervous system, where the own white blood cells are the myellin shells destroy the nerve fibers.
Auf Grund von Recherchen wird von der Anmelderin davon ausge gangen, daß es sich bei der Krankheit Multiple Sklerose um eine PAF-Stoffwechselstörung handelt, bei der ein körpereige ner chemischer Botenstoff, der sogenannte Blutplättchen-Akti vierungsfaktor PAF (engl. Kürzel für platelet activation fac tor) eine Schlüsselrolle spielt. Wird z. B. zu viel vom körpereigenen Botenstoff PAF - als Media tor zur Bekämpfung von Erregern - freigesetzt, können die da durch vermehrt aktivierten Leukozyten die Myellin-Hüllen der Nervenfasern im Gehirn schädigen und damit Unterbrechungen oder Kurzschlüsse der frei liegenden Nervenfasern verursachen, die wiederum die bekannten, spastischen Funktionsstörungen aus lösen.Based on research, the applicant assumes this that the disease is multiple sclerosis is a PAF metabolic disorder in which a body's own ner chemical messenger, the so-called platelet share crossing factor PAF (English abbreviation for platelet activation fac tor) plays a key role. Is z. B. too much of the body's own messenger substance PAF - as media to fight pathogens - released, they can the myellin envelopes of the Damage nerve fibers in the brain and thus interruptions or cause short circuits in the exposed nerve fibers, which in turn characterizes the well-known, spastic functional disorders to solve.
Durch Versuche wurde nun ermittelt, daß die Multiple Sklerose durch die Gabe eines an sich bekannten Extraktes aus den Blät tern von Ginkgo biloba erfolgreich therapiert werden kann. Es wurde gefunden, daß nur der flüssige Extrakt von Ginkgo bi loba hochwirksam ist, wenn dieser - unter Umgehung des Magen- Darm-Traktes - sublingual eingenommen, in die Mundschleimhäu te vollständig eindiffundiert bzw. dem Blutkreislauf, zur Über windung der Blut/Hirnschranke, direkt zugeführt wird.Trials have now shown that multiple sclerosis by the administration of a leaf extract known per se ginkgo biloba can be successfully treated. It was found that only the liquid extract from Ginkgo bi loba is highly effective if - bypassing the stomach - Intestinal tract - taken sublingually, in the oral mucosa completely diffused into the bloodstream, for transfer winding of the blood / brain barrier, is fed directly.
Unter Extrakten werden im wesentlichen flüssige Extrakte aus den Blättern von Ginkgo biloba verstanden, die als Hauptwirk stoff in Tinkturen oder in Infusionslösungen zur Verfügung stehen.Extracts are essentially liquid extracts the leaves of Ginkgo biloba understood as the main active available in tinctures or in infusion solutions stand.
Erfindungsgemäß geeignete Extrakte aus den Blättern von Ginkgo biloba sind z. B. Tebonin forte, rökan und Gingium als Mittel zur Behandlung von Durchblutungsstörungen im Handel. Extracts from the leaves of ginkgo suitable according to the invention biloba are e.g. B. Tebonin forte, Rökan and Gingium as a means for the treatment of circulatory disorders in the trade.
Die Verabreichung erfolgt zweckmäßigerweise 3 bis 4 mal täg lich nach dem Essen, wobei die Dosis individuell, dem Befin den des Patienten, angepaßt werden kann. Wird während des Schlafes ein sogenannter MS-Schub ausgelöst, kann die tägli che Dosis so gewählt werden, daß dieser ausbleibt. Die Nor maldosis pro Gabe beträgt 20 Tropfen, jeweils enthaltend Trockenextrakt aus Ginkgo-biloba-Blättern 40 mg - stand.: auf 9,6 mg Ginkgoflavonglykose.The administration is expediently 3 to 4 times a day Lich after eating, with the dose individually, depending on the that of the patient can be adjusted. Will during the A so-called MS surge triggered sleep, the daily che dose be chosen so that it does not appear. The Nor The maximum dose per dose is 20 drops, each containing Dry extract from Ginkgo biloba leaves 40 mg - as at: to 9.6 mg ginkgoflavone glycosis.
Die überraschende Wirksamkeit von flüssigen Extrakten aus den Blättern von Ginkgo biloba wurde an einer unter Multip ler Sklerose leidenden Patientin nachgewiesen und fachärzt lich bestätigt.The surprising effectiveness of liquid extracts the leaves of Ginkgo biloba were grown on one under multip Patient suffering from sclerosis is proven and specialist Lich confirmed.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19934328374 DE4328374A1 (en) | 1993-08-24 | 1993-08-24 | Use of an extract from the leaves of Ginkgo biloba |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19934328374 DE4328374A1 (en) | 1993-08-24 | 1993-08-24 | Use of an extract from the leaves of Ginkgo biloba |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE4328374A1 true DE4328374A1 (en) | 1995-03-02 |
Family
ID=6495848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19934328374 Withdrawn DE4328374A1 (en) | 1993-08-24 | 1993-08-24 | Use of an extract from the leaves of Ginkgo biloba |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE4328374A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2782008A1 (en) * | 1998-08-07 | 2000-02-11 | Sod Conseils Rech Applic | USE OF GINKGO BILOBA EXTRACTS FOR PREPARING A MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS |
| CN110339190A (en) * | 2018-04-08 | 2019-10-18 | 成都百裕制药股份有限公司 | Application of the ginkgoterpene lactone in preparation prevention or treatment multiple sclerosis drug |
-
1993
- 1993-08-24 DE DE19934328374 patent/DE4328374A1/en not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| AMLING, Rainer: Phytotherapeutika in der Neurolo- gie. In: Zeitschrift für Phytotherapie, 12, 1991, S.9-14 * |
| KLEIJNEN, Jos: Food supplements and their effi- cacy. In: Pharmaceutisch Weekblad Scientific edition, 14, 6, 1992, S.373-374 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2782008A1 (en) * | 1998-08-07 | 2000-02-11 | Sod Conseils Rech Applic | USE OF GINKGO BILOBA EXTRACTS FOR PREPARING A MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS |
| WO2000007592A1 (en) * | 1998-08-07 | 2000-02-17 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis |
| CN110339190A (en) * | 2018-04-08 | 2019-10-18 | 成都百裕制药股份有限公司 | Application of the ginkgoterpene lactone in preparation prevention or treatment multiple sclerosis drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Speirs et al. | The influence of sympathetic activity and isoprenaline on the secretion of amylase from the human parotid gland | |
| DE3876877T2 (en) | USE OF INDOLON DERIVATIVES FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF PARKINSONISM. | |
| DE3023588C2 (en) | Use clonidine or its hydrochloride with phentermine to quit smoking | |
| DE1902227A1 (en) | Medicines for psychotherapeutic use and processes for their manufacture | |
| DE69209414T2 (en) | Preparations that promote brain activity | |
| EP0065747A1 (en) | Nonapeptide for the treatment of symptoms caused by the withdrawal of drugs | |
| EP0185210B1 (en) | Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis | |
| DE4232899C2 (en) | Use of NADH and NADPH to treat Alzheimer's disease | |
| EP0289639B1 (en) | Use of trigonellin to revive, to stimulate and to enhance hair growth | |
| DE3500670C2 (en) | ||
| DE4328374A1 (en) | Use of an extract from the leaves of Ginkgo biloba | |
| Täschner | A controlled comparison of clonidine and doxepin in the treatment of the opiate withdrawal syndrome | |
| DE2529148A1 (en) | POWDER FOR MAKING A TASTY ORAL DOSAGE OF A Hematopoietic Agent | |
| DE68905657T2 (en) | USE OF ARGININE ASPARTATE FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CERTAIN COMMUNICATION. | |
| DE2824362A1 (en) | Pharmaceuticals for treating depression and insomnia - contg. L-tryptophan with vegetable oil in soft gelatin capsules | |
| EP0150248B1 (en) | Means for the treatment and the prophylaxis of uratic and mixed uratic lithiasis | |
| DE3626128C2 (en) | ||
| DE2513597B2 (en) | L-5-HYDROXYTRYPTOPHAN-L-GLUTAMATE MONOHYDRATE, METHOD OF ITS MANUFACTURING AND MEDICINAL PRODUCT | |
| DE69701139T2 (en) | USE OF LOFEXIDIN FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR TREATING THE HYPERACTIVITY CONCENTRATED WITH LOW CONCENTRATION | |
| Lomholt | Notes on the pharmacology of bismuth, with reference to its employment in the therapy of syphilis | |
| DE69516602T2 (en) | Use of bifemelan in the manufacture of a medicament for the treatment of hyperkinesia | |
| EP0305902B1 (en) | Medicament | |
| Witkin et al. | Effects of pentobarbital on punished behavior: Persistent increases with chronic administration | |
| DE3933738A1 (en) | NEW USE OF 2-AMINOTHIAZOL DERIVATIVES (TSH) | |
| DE4110620A1 (en) | Use of extract from Gingko biloba leaves - for treating sleep apnea, opt. co-administered with theophylline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8139 | Disposal/non-payment of the annual fee |